| Product Name | BHLHE40 Antibody, HRP conjugated |
|---|---|
| Description | Rabbit polyclonal antibody against BHLHE40 conjugated to HRP. |
| Synonyms | BHE40_HUMAN antibody; bHLHB2 antibody; bHLHe40 antibody; Class B Basic Helix Loop Helix Protein 2 antibody; Class B basic helix-loop-helix protein 2 antibody; Class E basic helix loop helix protein 40 antibody; Class E basic helix-loop-helix protein 40 antibody; Clast5 antibody; DEC1 antibody; Differentially expressed in chondrocytes protein 1 antibody; E47 interaction protein 1 antibody; EIP1 antibody; Enhancer of split and hairy related protein 2 antibody; Enhancer-of-split and hairy-related protein 2 antibody; SHARP 2 antibody; SHARP-2 antibody; Stimulated by retinoic acid gene 13 protein antibody; STRA13 antibody |
| Host | Rabbit |
| Clonality | Polyclonal |
| Conjugate | HRP |
| Immunogen | Recombinant human Class E basic helix-loop-helix protein 40 protein (184-302AA) |
| Isotype | IgG |
| Target | BHLHE40 |
| Reactivity | Human |
| Applications | ELISA |
| Form | Liquid |
| Diluent Buffer | Preservative: 0.03% Proclin 300Constituents: 50% Glycerol, 0.01M PBS, PH 7.4 |
| Uniprot | O14503 |
| Storage | Upon receipt, store at -20°C or -80°C. Avoid repeated freeze. |
| Background | Transcriptional repressor involved in the regulation of the circadian rhythm by negatively regulating the activity of the clock genes and clock-controlled genes. Acts as the negative limb of a novel autoregulatory feedback loop (DEC loop) which differs from the one formed by the PER and CRY transcriptional repressors (PER/CRY loop). Both these loops are interlocked as it represses the expression of PER1/2 and in turn is repressed by PER1/2 and CRY1/2. Represses the activity of the circadian transcriptional activator: CLOCK-ARNTL/BMAL1|ARNTL2/BMAL2 heterodimer by competing for the binding to E-box elements (5'-CACGTG-3') found within the promoters of its target genes. Negatively regulates its own expression and the expression of DBP and BHLHE41/DEC2. Acts as a corepressor of RXR and the RXR-LXR heterodimers and represses the ligand-induced RXRA and NR1H3/LXRA transactivation activity. May be involved in the regulation of chondrocyte differentiation via the cAMP pathway. |
| Supplier | Cusabio |
All Research Products are sold for laboratory RESEARCH USE ONLY and ARE NOT TO BE USED FOR HUMAN OR ANIMAL THERAPEUTIC OR DIAGNOSTIC APPLICATIONS. The information presented is believed to be accurate; however, said information and products are offered without warranty or guarantee since the ultimate conditions of use and the variability of the materials treated are beyond our control. Nothing disclosed herein is to be construed as a recommendation to use our products in violation of any patents. ARP American Research Products, Inc. does not submit its products for regulatory review by any government body or other organization, and we do not validate them for clinical, therapeutic or diagnostic use, or for safety and effectiveness. You are solely responsible for making sure that the way you use the products complies with applicable laws, regulations and governmental policies and for obtaining all necessary approvals, intellectual property rights, licenses and permissions that you may need related to your use. Under no circumstances shall ARP American Research Products, Inc. be liable for damages, whether consequential, compensatory, incidental or special, strict liability or negligence, breach of warranty or any other theory arising out of the use of the products available from ARP American Research Products, Inc. Nothing contained herein warrants that the use of the products will not infringe on the claims of any patents covering the product itself or the use thereof in combination with other products or in the operation of any process. ARP American Research Products, Inc. disclaims any and all representations or warranties of any kind whatsoever, express or implied, including without limitation any implied warranties of merchantability or fitness for a particular purpose, of non-infringement, or regarding results obtained through the use of any product, whether arising from a statute or otherwise in law or from a course of performance, dealing or usage of trade.
